Skip to main content
main-content

Genetics

Genetics

09-08-2018 | Non-small-cell lung cancer | News | Article

Broad-based genomic screening benefits questioned for advanced NSCLC

Most patients being treated in the community setting for advanced nonsquamous non-small-cell lung cancer do not benefit from the use of broad-based genomic sequencing, suggests a study comparing this approach with routine testing for only epidermal growth factor receptor and anaplastic lymphoma kinase alterations.

08-08-2018 | Non-small-cell lung cancer | News | Article

Molecular mechanisms of acquired osimertinib resistance explored

An analysis of patients with T790M-positive, advanced non-small-cell lung cancer who developed resistance to osimertinib points to heterogeneous underlying molecular mechanisms.

30-07-2018 | Breast cancer | News | Article

TGFB1 gene key determinant of breast fibrosis risk

Carriers of the C−509T allele in the transforming growth factor ß 1 gene have a significantly increased risk for late breast fibrosis following breast-conserving surgery and whole-breast irradiation for stage 0 to IIA breast cancer, researchers report.

11-05-2018 | Breast cancer | News | Article

Germline BRCA status may influence advanced TNBC chemotherapy choice

Testing for BRCA1 and BRCA2 mutations could inform the choice of chemotherapeutic agent in women with advanced triple-negative breast cancer, suggest the results of the TNT trial.

11-04-2018 | Non-small-cell lung cancer | News | Article

Concomitant mutations linked to poorer response in EGFR mutation-positive NSCLC

In patients with epidermal growth factor receptor-mutated non-small-cell lung cancer, the presence of concomitant mutations in other cancer-related genes is associated with worse outcomes in response to EGFR tyrosine kinase inhibitors, Chinese research suggests.

11-04-2018 | Leukaemia | News | Article

Molecular minimal residual disease predicts poor outcome in AML

The presence of molecular minimal residual disease, identified by next-generation targeted sequencing, is associated with a significantly increased risk for relapse or death in patients with acute myeloid leukemia, study findings indicate.

12-03-2018 | Oncology | News | Article

Telephone disclosure may be a valid option for revealing cancer genetic test results

For individuals who have undergone germline genetic testing, receiving the results via telephone could be a valid alternative to in-person disclosure, trial findings suggest.

18-01-2018 | Breast cancer | News | Article

Breast cancer survival not linked to BRCA status in young women

BRCA mutation status does not impact survival in young women with breast cancer, results of a large prospective cohort study show.

12-01-2018 | Prostate cancer | News | Article

Genetic risk model could guide prostate cancer screening

A polygenic hazard score that evaluates an individual’s age-related risk for developing prostate cancer could help guide personalized decision making about prostate-specific antigen screening, say researchers.

16-11-2017 | Colorectal cancer | News | Article

Mismatch repair deficiency testing underused for CRC patients in USA

Researchers have warned that underuse of mismatch repair deficiency testing “is a persistent and pervasive problem” in the USA, even among young adults with colorectal cancer where its use is unequivocally recommended.

15-08-2017 | Neuro-oncology | News | Article

Genetic testing recommended for schwannoma, meningioma in young patients

A high proportion of children and young adults with apparently solitary schwannoma or meningioma have mutations in known constitutional tumor predisposition genes, study data show.

14-08-2017 | Gastrointestinal cancer | News | Article

Deleterious germline mutations common in sporadic pancreatic cancer

Deleterious germline mutations are common in patients with pancreatic ductal adenocarcinoma who do not have a family history of the disease, research suggests.

09-08-2017 | Breast cancer | News | Article

Full breast cancer screening may benefit Ashkenazi Jewish women

Ashkenazi Jewish women with breast cancer may benefit from comprehensive genetic screening for all breast cancer genes, not just founder mutations in BRCA1 or BRCA2, US researchers report.

29-06-2017 | Oncology | News | Article

Routine detection of actionable mutations feasible, but benefit limited to a few

ProfiLER-01 study data suggest that high-throughput genomic testing can be incorporated into routine practice, but only a subset of patients derive a clinical benefit.

25-05-2017 | Non-small-cell lung cancer | News | Article

Pembrolizumab receives agnostic approval for MSI-H/dMMR tumors

Click through to read more on these announcements

03-04-2017 | Gastrointestinal cancer | News | Article

Optimal adjuvant imatinib duration influenced by KIT mutation status

Patients with gastrointestinal stromal tumors harboring KIT proto-oncogene receptor tyrosine kinase exon 11 deletion mutations derive the greatest benefit from 3 years of adjuvant imatinib treatment, researchers report.

22-02-2017 | Oncology | News | Article

Genetic profiling may aid treatment decisions in MDS

Mutations in the TP53 gene are the strongest independent predictor of reduced survival after allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome, results of a genetic profiling study show.

13-02-2017 | Breast cancer | News | Article

Disparity between desire for, availability of BRCA gene testing

The majority of women newly diagnosed with early-stage breast cancer would like to be tested for BRCA1 and BRCA2 mutations, but only a small proportion undergo genetic testing.

01-02-2017 | Gynaecological cancer | News | Article

TCGA analysis reveals potential cervical cancer therapeutic targets

A comprehensive genomic and molecular analysis of cervical cancers provides insight into potential therapeutic targets and identifies distinct molecular subtypes of the disease.

21-10-2016 | HBV | News | Article

HBV variants limit NA therapy response

Detectable baseline mutations in the basal core promoter and/or precore regions of hepatitis B virus are associated with a reduced likelihood of hepatitis B surface antigen loss during long-term nucleos(t)ide analogue treatment, suggest researchers.

Image Credits